 | |
| Clinical data | |
|---|---|
| Other names | MK-1022 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Patritumab deruxtecan (MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer. [1] [2] [3]
References
- ^ Yu, H.A.; Baik, C.S.; Gold, K.; Hayashi, H.; Johnson, M.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W-C.; Yang, J.; Karam, S.; Qi, Z.; Qiu, Y.; Chen, S.; Yu, C.; Jänne, P.A. (September 2020). "LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC". Annals of Oncology. 31: S1189–S1190. doi: 10.1016/j.annonc.2020.08.2295. S2CID 225184933.
- ^ Krop, Ian E.; Masuda, Norikazu; Mukohara, Toru; Takahashi, Shunji; Nakayama, Takahiro; Inoue, Kenichi; Iwata, Hiroji; Toyama, Tatsuya; Yamamoto, Yutaka; Hansra, Damien Mikael; Takahashi, Masato; Osaki, Akihiko; Koyama, Kumiko; Inoue, Tatsuya; Yonekura, Takatoshi; Mostillo, Joseph; Ohwada, Shoichi; Tanaka, Yoshimi; Sternberg, David W.; Yonemori, Kan (1 June 2022). "Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)". Journal of Clinical Oncology. 40 (16_suppl): 1002. doi: 10.1200/JCO.2022.40.16_suppl.1002. S2CID 249454563.
- ^ Jänne, Pasi A.; Baik, Christina; Su, Wu-Chou; Johnson, Melissa L.; Hayashi, Hidetoshi; Nishio, Makoto; Kim, Dong-Wan; Koczywas, Marianna; Gold, Kathryn A.; Steuer, Conor E.; Murakami, Haruyasu; Yang, James Chih-Hsin; Kim, Sang-We; Vigliotti, Michele; Shi, Rong; Qi, Zhenhao; Qiu, Yang; Zhao, Lihui; Sternberg, David; Yu, Channing; Yu, Helena A. (1 January 2022). "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer". Cancer Discovery. 12 (1): 74–89. doi: 10.1158/2159-8290.CD-21-0715. PMC 9401524. PMID 34548309.
|
| |
| Clinical data | |
|---|---|
| Other names | MK-1022 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Patritumab deruxtecan (MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer. [1] [2] [3]
References
- ^ Yu, H.A.; Baik, C.S.; Gold, K.; Hayashi, H.; Johnson, M.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W-C.; Yang, J.; Karam, S.; Qi, Z.; Qiu, Y.; Chen, S.; Yu, C.; Jänne, P.A. (September 2020). "LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC". Annals of Oncology. 31: S1189–S1190. doi: 10.1016/j.annonc.2020.08.2295. S2CID 225184933.
- ^ Krop, Ian E.; Masuda, Norikazu; Mukohara, Toru; Takahashi, Shunji; Nakayama, Takahiro; Inoue, Kenichi; Iwata, Hiroji; Toyama, Tatsuya; Yamamoto, Yutaka; Hansra, Damien Mikael; Takahashi, Masato; Osaki, Akihiko; Koyama, Kumiko; Inoue, Tatsuya; Yonekura, Takatoshi; Mostillo, Joseph; Ohwada, Shoichi; Tanaka, Yoshimi; Sternberg, David W.; Yonemori, Kan (1 June 2022). "Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)". Journal of Clinical Oncology. 40 (16_suppl): 1002. doi: 10.1200/JCO.2022.40.16_suppl.1002. S2CID 249454563.
- ^ Jänne, Pasi A.; Baik, Christina; Su, Wu-Chou; Johnson, Melissa L.; Hayashi, Hidetoshi; Nishio, Makoto; Kim, Dong-Wan; Koczywas, Marianna; Gold, Kathryn A.; Steuer, Conor E.; Murakami, Haruyasu; Yang, James Chih-Hsin; Kim, Sang-We; Vigliotti, Michele; Shi, Rong; Qi, Zhenhao; Qiu, Yang; Zhao, Lihui; Sternberg, David; Yu, Channing; Yu, Helena A. (1 January 2022). "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer". Cancer Discovery. 12 (1): 74–89. doi: 10.1158/2159-8290.CD-21-0715. PMC 9401524. PMID 34548309.